In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple ...
Good day, everyone, and welcome to the PDF Solutions, Inc. Conference Call to discuss its Financial Results for the Fourth Quarter and year end 2025 ending Wednesday, 12/01/2025. If you have not yet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results